Real-world characteristics of patients with asthma initiating fluticasone furoate/umeclidinium/vilanterol single-inhaler triple therapy in Japan | Synapse

⌘+K

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real-World Safety and Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Asthma: Final Analysis of a Post-Marketing Surveillance in Japan2025 · 1 citations
2Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthmaOriginal Research · 2019 · 1 citations
3Real-World Effects of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol in Chinese Patients with AsthmaRetrospective Study · 2026
4C35-01 Real-World Evaluation of Medication Adherence to Single-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease: The Life StudyCohort Study · 2026
5Correction: Akiyama et al. Comparison of the Risk of Pneumonia Between Fluticasone Furoate/Umeclidinium/Vilanterol and Multiple-Inhaler Triple Therapy in Patients with COPD Using Health Insurance Claims Data: Final Analysis of Post-Marketing Database Surveillance in Japan. J. Clin. Med. 2025, 14, 4697Original Research · 2026

More from Respiratory Investigation

More from McMaster University